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Abstract
Importance—Persistent congestion is associated with worse outcomes in acute heart failure
(AHF). Mineralocorticoid receptor antagonists at high doses may relieve congestion, overcome
diuretic resistance, and mitigate the effects of adverse neurohormonal activation in AHF.
Objective—To assess the impact of high dose spironolactone in addition to usual care on Nterminal pro-B-type natriuretic peptide (NTproBNP) levels compared to usual care alone.
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Design—Double blind, placebo (or low dose)-controlled, multicenter, randomized clinical trial
Setting—Twenty-two acute care hospitals in the Unites States

Address correspondence to: Javed Butler, MD, MPH, Cardiology Division, Stony Brook University, T-16, Room 080, Stony Brook,
NY 11794. Telephone: (631) 444-1066 Fax: (631) 444-1054, javed.butler@stonybrookmedicine.edu.
Trial Registration: Clinicaltrials.gov identifier: NCT02235077
The principal investigator Dr. Butler had full access to all the data in the study and takes responsibility for the integrity of the data and
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Participants—Patients with AHF and NTproBNP level of ≥1000 pg/mL or B-type natriuretic
peptide ≥250 pg/mL regardless of ejection fraction, previously receiving no or low-dose (12.5 or
25 mg daily) spironolactone
Intervention—High dose spironolactone (100 mg) vs. placebo or 25 mg spironolactone (usual
care) daily for 96 hours
Main Outcomes Measures—The primary endpoint was change in NTproBNP levels from
baseline to 96 hours. Secondary endpoints included clinical congestion score, dyspnea assessment,
net urine output, and net weight change. Safety endpoints included hyperkalemia and changes in
renal function.

Author Manuscript

Results—A total of 360 patients were randomized (median age 65 years, 36% women, 65%
Caucasian, and median left ventricular ejection fraction of 34%. Baseline median NTproBNP
levels were 4601 (2697, 9596) pg/ml in the high-dose spironolactone group and 3753 (1968, 7633)
pg/ml in the usual care group. There was no significant difference in the log NTproBNP reduction
between the two groups (−0.55 [−0.92, −0.18] with high-dose spironolactone and −0.49 [−0.98,
−0.14] with usual care, P=0.57). None of the secondary endpoint or day-30 all-cause mortality or
heart failure hospitalization rate differed between the two groups. The changes in serum potassium
and estimated glomerular filtration rate at 24, 48, 72, and 96 hr. were similar between the two
groups.
Conclusion and Relevance—Addition of high dose spironolactone to usual care in patients
with AHF for 96 hours was well tolerated but did not improve either the primary or any of the
secondary efficacy endpoints.
Keywords

Author Manuscript

Acute heart failure; aldosterone; heart failure; hospitalization; mineralocorticoid receptor
antagonist; natriuretic peptide; spironolactone
Acute heart failure (AHF) accounts for over a million hospitalizations in the United States
annually.1 Hospitalizations for HF are associated with a mortality or readmission risk of
~30% at 60-days and ~50% by 6-month post discharge.2, 3 The already activated reninangiotensin-aldosterone-system (RAAS) in chronic heart failure may be further accentuated
in AHF.4 The use of intravenous loop diuretics intensifies secondary hyperaldosteronism in
these patients.5 Beyond myocardial and vascular adverse effects, hyperaldosteronism
directly contributes to diuretic resistance in AHF.6 Elevated aldosterone levels in AHF are
associated with increased risk of cardiovascular mortality and HF readmission.7
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The role of low dose mineralocorticoid receptors antagonists (MRA) therapy as a
neurohormonal antagonist is well established for the treatment of chronic heart failure and
reduced ejection fraction. However, the role of high dose MRA therapy in AHF remains
uncertain. Several studies have shown that mineralocorticoid receptors antagonists (MRA) at
high doses result in significant natriuresis and help overcome diuretic resistance.8, 9
However, there have been concerns regarding hyperkalemia and renal failure with MRA use
especially with high doses.10 A single-center, single-blind, non-randomized, trial suggested
benefit with high dose MRA therapy in AHF, including lower natriuretic peptide levels, less
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congestion, better renal function, and less need for intravenous diuretic.11 Accordingly, we
performed the Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy
in Heart Failure (ATHENA-HF) trial to test the hypothesis that high dose spironolactone use
in patients with AHF will have a beneficial impact in patients with AHF.

METHODS
Study Oversight

Author Manuscript

The ATHENA-HF trial was sponsored by the National Heart, Lung, and Blood Institute and
conducted by the Heart Failure Clinical Research Network. The protocol was approved by
the network’s protocol review committee and monitored by the network’s data and safety
monitoring board. The ethics committee at each participating site approved the trial. Data
collection, management, and analysis were performed at the network’s coordinating center
at Duke Clinical Research Institute. All authors reviewed and approved the manuscript and
assume full responsibility for the accuracy and completeness of the data and for the fidelity
of this report to the study protocol, which is available with the full text of this article.
Study Patients

Author Manuscript

The eligibility criteria for the ATHENA-HF trial included a clinical diagnosis of heart failure
with at least one sign and one symptoms of AHF and with an NT-proBNP level of ≥1000
pg/mL or BNP ≥250 pg/mL, regardless of ejection fraction, measured within 24 hours of
randomization. Patients were eligible if they were either (1) receiving no spironolactone or
(2) receiving low-dose spironolactone (12.5 or 25 mg per day) at home prior to admission.
Patients were also required to have serum potassium concentration ≤5.0mmol/L, estimated
glomerular filtration rate (eGFR) ≥30 mL/min/1.73m2 and systolic blood pressure >90
mmHg. Patients receiving eplerenone were excluded since in an acute setting it may not be
easily known if the patient had previously been intolerant to spironolactone. Patients already
taking more than 25 mg of spironolactone were excluded.
Study Design

Author Manuscript

Detailed study design for the ATHENA-HF trial has been described previously.12 Briefly,
this was a randomized, double blind, placebo controlled trial assessing the impact of high
dose spironolactone in addition to usual care vs. usual care on N-terminal pro-B-type
natriuretic peptide (NT-proBNP) levels at 96 hours among patients hospitalized for AHF.
The study intervention was initiated within 24 hours of the first dose of intravenous
diuretics. Patients not on spironolactone were randomized to 100 mg spironolactone or
placebo. Those on low dose spironolactone prior to admission were randomized to 100 mg
or 25 mg per day in the usual care alone arm; placebo was not given to these patients to
avoid ethical concerns with discontinuing chronic stable therapy. Randomization was
double-blind for both comparator strata and was not stratified according to previous lowdose spironolactone. All other medications, including diuretics, were left at the discretion of
the treating physician. The study drug was discontinued after 96 hours and further MRA use
was left to the treating physician’s discretion. Data on left ventricular ejection fraction
measured within 6 months prior to randomization were collected; when unavailable, it was
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assessed during hospitalization. Algorithms were suggested for the management of
worsening creatinine and hyperkalemia during the blinded period.
Study Endpoints

Author Manuscript

The primary endpoint was the proportional change in the log NT-proBNP levels from
randomization to 96 hours (or at discharge if discharge was earlier than 96 hours). Multiple
secondary endpoints from randomization to 96 hours were assessed. These included: a)
clinical congestion score, calculated by summing the individual scores for orthopnea, jugular
venous distension, and pedal edema on a standardized 4-point scale ranging from 0 to 3;13 b)
dyspnea relief, measured by a Likert scale (ranging from 1=markedly improved to 7=
markedly worse) and by the Visual Analog Scale (ranging from 0 to 100, with higher values
indicating better status); c) cumulative net urine output on a daily basis for up to 96 h; d) net
weight change from baseline to 96 h or discharge (whichever came first); e) furosemide
equivalents of loop diuretic dose at discharge, and f) development of in-hospital worsening
HF, with signs and symptoms requiring additional therapy. Exploratory endpoints included a
day-30 post randomization composite of all-cause mortality, all-cause readmission, or
outpatient worsening heart failure (heart failure related readmission or emergency
department visit or need for outpatient intravenous diuretics). Participants were also
contacted by telephone at 60±3 days to assess vital status. Safety endpoints included change
in serum creatinine, estimated glomerular filtration rate, and incidence of moderate
(>5.5mmol/L) and severe hyperkalemia (>6.0mmol/L) during the 96-hour treatment period.
Statistical Analysis

Author Manuscript
Author Manuscript

It was anticipated that 25% of subjects enrolled would be on low-dose MRA at
randomization. Assuming a 20% further reduction in NT-proBNP from randomization in the
MRA group compared to placebo and a 10% reduction in those on low-dose MRA at
baseline, yielded an overall benefit of 17.5% for the study population. With a 1:1
randomization and a two-sided type I error rate of 0.05, a total of 360 subjects provided
approximately 85% power. Randomization was conducted using a permuted block design
with stratification based on site and MRA usage at enrollment. The primary analysis used a
linear regression model with an indicator variable for treatment assignment, an indicator for
MRA use prior to admission, and the log of the baseline NT-proBNP level. We opted to
analyze log-transformed NT-proBNP levels because of better distributional properties and
therefore improvements in the underlying assumptions of the statistical models involving
NT-proBNP. Missing values of the 96-hour NT-proBNP levels (22 in usual care and 23 in
high dose spironolactone group) were imputed using a multiple imputation algorithm. In a
sensitivity analysis, values missing due to death were imputed to the worst possible value.14
This analysis accounted for low-dose MRA prior to admission using a stratified version of
the Wilcoxon-Mann-Whitney test. For binary outcomes, chi-square tests and Fisher’s exact
test were used for unadjusted comparisons. Unadjusted time-to-event comparisons were
conducted using Kaplan-Meier survival estimates and log-rank tests. Cox proportional
hazards regression models were used to estimate hazard ratios (HR) and 95% confidence
intervals (CI). Four pre-specified subgroup analyses were conducted including baseline low
dose MRA use, gender, ejection fraction (greater than versus less than or equal to 45%), and
age (greater than versus equal to or less than 65 years). Data are presented as median
JAMA Cardiol. Author manuscript; available in PMC 2017 November 07.
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(interquartile range [IQR]). For primary and secondary end points, a P value less than .05
was considered significant. For subgroup analyses, a treatment by subgroup interaction p
less than .01 was considered significant. All analyses were conducted with the use of SAS
statistical software version 9.2.

RESULTS
Study Patients

Author Manuscript

From December 2014 to April 2016, 360 patients were enrolled from 22 sites for an
enrollment rate of ~1 patient/site/month. A total of 182 patients were randomized to highdose spironolactone plus usual care and 178 to usual care alone (placebo N=132 or
continued low dose spironolactone N=46) Figure 1. Baseline characteristics of the patient
population are shown in Table 1. Note that the use of medication at baseline reflects those
that the patients were given at randomization, which was within 24 hours of first dose of I.V.
diuretics. The number of patients on spironolactone was lower at randomization than preadmission as home medications were discontinued at admission for some patients. The
median age was 65 years, 36% were females, and 56% were White. Median ejection fraction
was 34%; 93 patients (26%) had ejection fraction >45%. Median systolic blood pressure was
122 mmHg, heart rate was 79 bpm, serum potassium concentration was 4.0 meq/L, serum
creatinine was 1.2 mg/dl, and estimated glomerular filtration rate (eGFR) was 56 ml/min.
Efficacy
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Baseline median (interquartile range) NTproBNP levels were 4601 pg/ml (IQR, 2697, 9596
pg/ml) in the spironolactone and 3753 pg/ml (IQR, 1968–7633 pg/ml) in the usual care
group. All randomized patients completed the study. There was no significant difference in
the primary endpoint between the two groups (log NTproBNP change −0.55; −0.92, −0.18
in the spironolactone and −0.49; −0.98, −0.14 in the usual care arm; P=0.57). Changes in log
NT-proBNP were similar in analyses using only complete cases, i.e. without imputation
(−0.56; −0.96, −0.19 in the spironolactone and −0.50; −0.99, −0.14 in the usual care arm;
P=0.57). None of the secondary endpoint including dyspnea score (Likert and Visual Analog
scales), clinical congestion score, net urine output, weight change, requirement for loop
diuretics, and in hospital worsening heart failure were different between the two groups
(Table 2). Of note, NT-proBNP levels in Table 1 (on-site qualification values before
randomization) vs. Table 2 (core lab values before treatment initiation) were drawn at
different times and patients in the two groups may have had different treatments and
responses to them in the interim. At discharge, mean furosemide dose (in IV furosemide
equivalents) was 89.5 mg in the spironolactone vs. 98.0 mg in the placebo group. In the
spironolactone group, 26 patients (14%) were discharged on spironolactone (1 on 50 mg, 17
on 25 mg, and 8 on 12.5 mg) vs. 35 (20%) in the placebo group (2 on 50 mg, 25 on 25 mg,
and 8 on 12.5 mg). At 96 h, thiazide use was 3% in the usual care and 4% in the high-dose
spironolactone group. Median time from randomization to discharge was 4 (2, 7) days in
both groups. Two and 7 patients in the usual care and, 2 and 5 in high-dose spironolactone
group died during the index hospitalization and through day 30 respectively. There was no
difference in time to first heart failure readmission, emergency visit, or death between the
two groups (adjusted HR 1.22, 95%CI 0.68, 2.19; P=0.50; Figure 2). There was no
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difference in all-cause mortality at day-60. There was no difference in day-30 MRA use
between the two groups (36% usual care alone vs. 31% high-dose spironolactone group,
p=0.24).
Safety

Author Manuscript

High dose spironolactone was well tolerated. The changes in serum potassium, creatinine,
and estimated glomerular filtration rate from baseline to 24, 48, 72, and 96 hr is shown in
Table 3. Only one patient in the usual care group and none in the high dose spironolactone
group experienced serum potassium levels between 5.5–5.9 mmol/L and no one had
potassium concentration > 6.0 mmol/L during the 96 hours of study treatment. Serious
adverse events by day-30 were reported in 84 (47%) patients in the usual care group and 79
(43%) patients in the high-dose spironolactone group (P=0.47). Worsening renal function,
defined as an increase of 0.3 mg/dl in creatinine from baseline through 96 hours, occurred in
51/182 (28%) in the high-dose spironolactone group and 57/178 (32%) in the usual care
group (P=0.42). No differences between groups were observed in terms of changes in heart
rate or blood pressure levels during treatment.
Sub-Group Analysis

Author Manuscript

No differences were observed in the primary endpoint between patients randomized to high
dose spironolactone or usual care stratified by age, gender, or use of low dose spironolactone
at baseline (Supplementary Figure). The change in log NTproBNP levels at 96 hours or at
earlier discharge in the spironolactone and usual care groups respectively among patients
with ejection fraction ≤45%was −0.55 (−0.92, −0.19) and −0.54 (−0.99, −0.15), and in those
with ejection fraction >45% was −0.53 (−1.03, −0.14) and −0.42 (−0.64, −0.03) (interaction
P=0.078). The results were similar when only complete cases were analyzed without
imputation (ejection fraction ≤45%: spironolactone −0.56 [−0.92, −0.20] vs. usual care
−0.56 (−1.01, −0.15]; ejection fraction >45%: spironolactone −0.57 [−1.11, −0.19] vs. usual
care −0.43 [−0.64, −0.09]).

DISCUSSION

Author Manuscript

In this study, which represents the first double blind multicenter trial assessing the efficacy
and safety of high dose spironolactone in AHF, there was no benefit or risk seen with active
intervention over usual care on either the primary or any of the secondary endpoints. These
include changes in NTproBNP levels, urine output, weight changes, symptoms or congestion
score. These results are in contrast to some of the earlier mechanistic and clinical data that
suggested increased urine output and less congestion with the use of high dose MRA
therapy. High dose spironolactone therapy was well tolerated without any significant risk of
hyperkalemia or worsening renal function in the population of patients who met the
eligibility criteria for the ATHENA-HF trial.
The eligibility criteria for ATHENA-HF were chosen to represent a generalizable AHF
population. The inclusion criteria of glomerular filtration rate >30 ml/min resulted in a
cohort with a median rate of 56 ml/min. Both study groups had significant diuresis and lost
over 6 lbs. of weight in the first 96 hr. or by earlier discharge. It is possible that targeting
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diuretic resistant patients with lower glomerular filtration rate may lead to better results with
high dose spironolactone. No difference was seen in the use of diuretic doses between the
two study arms, so it does not appear that high-dose spironolactone led to a selective early
reduction in loop diuretic doses in the active intervention. No differences were noted
between patients who were MRA naïve vs. those on low dose spironolactone at baseline and
hence the neutral results cannot be attributed to chronic MRA use in a proportion of patients.
Is it possibility that 100 mg spironolactone is not a high enough dose and that higher doses
are needed. This possibility is intriguing considering that previous smaller heart failure
studies have used up to 200 mg of spironolactone similar to the doses used in cirrhosis.8
This approach may be explored in the future considering the safety of 100 mg
spironolactone in the ATHENA-HF trial. Emerging data with novel potassium binders
reducing the risk of hyperkalemia may further facilitate such a study.10 Spironolactone is a
prodrug that is converted to active metabolite canrenone, which is responsible for its
mineralocorticoid effects.15 Considering the short duration of AHF hospitalizations in the
United States averaging at 4–5 days,16 using intravenous canrenoate with faster onset of
action may be more beneficial. Similarly, new non-steroidal MRA finerenone that does not
require conversion to an active metabolite may be more useful in the AHF setting.17

Author Manuscript

There were no safety concerns raised by the use of high dose spironolactone in this trial.
There is a substantial risk of hyperkalemia even with lower doses of spironolactone in
patients with chronic heart failure.10 With the active changes in glomerular filtration rate and
blood pressure commonly encountered in the setting of AHF, the risk of hyperkalemia with
high dose spironolactone is of concern. However, our study confirms that in the hospital
setting high dose spironolactone use is safe in patients with relatively preserved renal
function and with the implementation of other precautions and protocols such as those used
in this trial. These data are encouraging for future research with either higher dose MRA in
AHF than used in ATHENA HF, or in patients with worse renal function and diuretic
resistance.
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There were no differences in the efficacy or safety of high dose spironolactone therapy in
any of the pre-specified sub-groups based on age, gender, or previous use of MRA.
Interesting, while no differences were seen among patients with ejection fraction ≤45%, in
patients with ejection fraction >45%, spironolactone intervention led to a numerically higher
reduction in log NTproBNP levels with a trend toward a significant treatment-by-subgroup
interaction. Though the trial was not powered to assess differences among patients with
reduced vs. preserved ejection fraction, these data are intriguing as the Renal Optimization
Strategies Evaluation (ROSE) trial also showed a differential trend with low dose dopamine
use in AHF patients between those with preserved vs. reduced ejection fraction.18 While it is
a standard for chronic heart failure trials to study patients with reduced and preserved
ejection fraction separately, a number of recent AHF trials have included patients regardless
of ejection fraction. The results of the ATHENA-HF trials provide data to encourage further
study of the differences between these two patient populations in the AHF setting.
Our study has several limitations. First, the duration of the treatment (96 h or until discharge,
whichever came first) was relatively short. Considering that spironolactone may take few
days to convert to its active metabolites, especially in the presence of hepatic congestion, we
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cannot exclude the possibility that longer treatment duration may have shown differences
between the two groups. Second, data on the primary endpoint (change in NT-proBNP
levels) were missing for approximately 12% of the study population. However, imputed,
worst-possible-value, and raw analyses all pointed to a neutral effect of spironolactone on
NT-proBNP levels. Third, in order for the trial to represent better the real-world population
with AHF, we included a number of patients (25%) already receiving low-dose MRA at
home and this may have influenced the treatment effect, thus contributing towards the
neutral results. Of note, there was no differential effect of high-dose spironolactone between
low-dose and no baseline MRA strata. Fourth, our study was not powered to explore
differences according to ejection fraction. Finally, we excluded patients with glomerular
filtration rate ≤30 ml/min and therefore our results, especially regarding safety, cannot be
extrapolated to these patients.
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In conclusion, high dose spironolactone in AHF was not associated with improvement in
either the primary or the secondary outcomes in the ATHENA-HF trial. This intervention
was safe and well tolerated. Future research should study higher doses and patients with
diuretic resistance and should explore differences between patients with preserved vs.
reduced ejection fraction.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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KEY POINTS
Question
Does addition of high-dose spironolactone in patients with acute heart failure lower
natriuretic peptide levels and improve outcomes better than usual care?
Findings
High-dose spironolactone use in acute heart failure was not associated with improvement
in natriuretic peptide levels, symptoms, congestion, urine output, weight loss, or clinical
outcomes than usual care group.
Meaning

Author Manuscript

Routine use of high-dose spironolactone in acute heart failure is not recommended.
Further studies targeting specifically diuretic resistant patients with high-dose
spironolactone are needed.
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Figure 1.

CONSORT Flow Diagram

Author Manuscript
Author Manuscript
JAMA Cardiol. Author manuscript; available in PMC 2017 November 07.

Butler et al.

Page 12

Author Manuscript
Author Manuscript
Figure 2. Time to first heart failure re-hospitalization, emergency room visit, or death
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There were no significant differences noted in the post-discharge outcomes among patients
randomized to the usual care alone vs. the high-dose spironolactone group
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Table 1
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Baseline Patient Characteristics
Baseline Characteristics

Usual care alone (N=178)

High-dose spironolactone (N=182)

Demographics
Age (yr.)

65 (54, 74)

65 (57, 76)

64 (36)

65 (36)

White - no. (%)

99 (56)

101 (55)

Black - no. (%)

77 (43)

74 (41)

Others - no. (%)

2 (1)

7 (4)

6 (3)

2 (1)

Female - no. (%)
Race

Hispanic or Latino - no. (%)
Past Medical History – N (%)

Author Manuscript

Myocardial Infarction

52 (30)

51 (28)

Hypertension

142 (81)

159 (87)

Stroke

26 (15)

29 (16)

Atrial fibrillation

84 (48)

88 (50)

Chronic Lung Disease

43 (24)

39 (21)

Diabetes Mellitus

74 (42)

72 (40)

Chronic Kidney Disease

54 (31)

43 (24)

Obstructive Sleep Apnea

41 (25)

41 (25)

25 (15)

31 (17)

112 (63)

105 (58)

Beta blockers

132 (74)

135 (74)

Mineralocorticoid receptor antagonists

21 (12)

19 (11)

Loop diuretics

169 (95)

177 (97)

Current smoker
Baseline Treatment - N (%)a
Angiotensin converting enzyme inhibitor or angiotensin receptor
blocker

Author Manuscript
Author Manuscript

Furosemide equivalent dose (median, mg)

80 (40, 160)

80 (40, 160)

Furosemide equivalent dose (mean, mg)

118.8 ± 94.4

122.5 ± 113.8

3 (2)

3 (2)

Digoxin

19 (11)

15 (8)

Hydralazine

47 (26)

44 (24)

Long-acting Nitrates

33 (19)

35 (19)

Calcium channel blockers

23 (13)

36 (20)

Statin

101 (57)

104 (57)

Implanted defibrillator

35 (42)

23 (35)

Biventricular pacemaker

31 (37)

28 (42)

114 (64)

120 (66)

30 (20, 45)

35 (21, 50)

Thiazide diuretics

Clinical Characteristics
Heart failure hospitalizations in past year, no. (%)
Left ventricular ejection fraction – no. (%)
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Baseline Characteristics

Usual care alone (N=178)

High-dose spironolactone (N=182)

140 (79)

123 (69)

Proportion with ejection fraction <45% – no (%)

Author Manuscript

Ischemic etiology - no. (%)

117 (66)

109 (60)

123 (108, 138)

120 (106, 138)

Heart rate per minute

80 (70, 94)

78 (70, 90)

Body mass index kg/m2b

32 (27, 38)

30 (25, 35)

Jugular venous pulse ≥10 cm - no. (%)

126 (74)

135 (76)

Rales - no. (%)

99 (56)

112 (62)

Edema - no. (%)

142 (80)

139 (77)

Orth0pnea - no. (%)

154 (87)

151 (85)

New York Heart Association Class III or IV - no. (%)

153 (86)

149 (85)

Fatigue frequent or continuous – no (%)

151 (86)

156 (86)

Systolic blood pressure - mmHg

Dyspnea frequent or continuous – no (%)

Author Manuscript

151 (86)

150 (83)

65 (40, 75)

60 (45, 75)

140 (138, 142)

140 (138, 142)

4.0 (3.6, 4.3)

3.9 (3.6, 4.3)

22 (17, 31)

23 (16, 33)

1.3 (1.0, 1.5)

1.2 (1.0, 1.5)

55 (46, 71)

58 (45, 75)

B-type natriuretic peptide, pg/ml (N=156)c

1055 (502, 1581)

1131 (680, 1986)

N-terminal pro B-type natriuretic peptide, pg/ml (N=204)c

4176 (1936, 7456)

(2472, 10048)

Dyspnea – visual analog scale
Laboratory Values
Sodium - mEq/L
Potassium - mEq/L
Blood urea nitrogen - mg/dL
Creatinine - mg/dL
Glomerular filtration rate - ml/min/1.73

m2

Values shown are median (25th, 75th) or count (%)
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a

At the time of randomization

b

p<0.05

c

Site-based qualifying values
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Table 2
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Primary and Secondary Outcomes
Outcomes

Usual care Alone

High dose spironolactone

P

Primary endpoint
Log N-terminal pro B-type natriuretic peptide
Baseline

8.23 (7.58, 8.94)

8.43 (7.90, 9.17)

96 hours (or earlier discharge) – with multiple imputation for missing values

7.64 (6.93, 8.45)

7.89 (7.19, 8.68)

−0.49 (−0.98, −0.14)

−0.55 (−0.92, −0.18)

7.55 (6.91, 8.31)

7.81 (7.06, 8.59)

−0.50 (−0.99, −0.14)

−0.56 (−0.96, −0.19)

Change - with multiple imputation for missing values
96 hours (or earlier discharge) – no imputation, complete cases only
Change - with multiple imputation for missing values

0.57

0.57

Secondary endpoints
N-terminal pro B-type natriuretic peptide, pg/ml

Author Manuscript

Baseline

3753 (1968, 7633)

4601 (2697, 9596)

96 hours (or earlier discharge) – with multiple imputation for missing values

2080 (1025, 4675)

2672 (1326, 5896)

−1072 (−3182, −231)

−1796 (−3883, −571)

1898 (1003, 4046)

2461 (1168, 5366)

−1060 (−2856, −238)

−1774 (−3763, −586)

Change - with multiple imputation for missing values
96 hours (or earlier discharge) – no imputation, complete cases only
Change - with multiple imputation for missing values

0.76

0.61

Clinical congestion score
Baseline

11 (9, 12)

10 (9, 12)

4 (2, 6)

4 (2, 7)

−6 (−8, −4)

−6 (−8, −4)

0.41

2 (1, 3)

2 (1, 3)

0.31

Baseline

65 (40, 75)

60 (45, 75)

96 hours (or earlier discharge)

83 (70, 90)

80 (65, 90)

15 (5, 30)

15 (2, 30)

0.61

96 hours (or earlier discharge)
Change
Dyspnea
Likert Score (96 hours or earlier discharge)
Visual Analog Scale

Author Manuscript

Change

Net urine output, ml (cumulative)
24 h

1183 (510, 1955)

1100 (483, 2131)

0.76

48 h

2282 (1155, 4135)

2484 (1203, 4411)

0.44

72 h

3810 (2011, 5565)

4171 (2053, 6040)

0.53

96 h

5584 (2924, 8132)

6086 (2780, 8420)

0.57

Baseline

207.1 (171.0, 250.4)

195.0 (162.6, 237.0)

96 hours (or earlier discharge)

198.9 (167.6, 243.6)

185.1 (158.5, 230.8)

−6.1 (−11.2, −1.8)

−7.3 (−13.0, −2.0)

Weight change, Ibs

Change

0.33

Author Manuscript

Furosemide equivalent diuretic dose, mg
Baseline

160 (120, 320)

96 hours (or earlier discharge)
Change

160 (100, 320)

80 (40, 240)

80.0 (40, 200)

−80 (−160, 0.0)

−80.0 (−160, 0)

Worsening heart failure, N (%)
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Outcomes
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Usual care Alone

High dose spironolactone

P

Inpatient

31 (18)

33 (19)

0.76

Outpatient (through day 30)

17 (10)

19 (11)

0.76

Values shown are median (25th, 75th) or count (%).
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0.20 (−0.40, 0.55)

0.20 (−0.30, 0.60)

0.05 (−0.05, 0.20)

0.02 (−1.10, 0.20)

0.08 (−0.08, 0.22)

0.10 (−0.02, 0.33)

72 h

96 h

24 h

48 h

72 h

96 h

0.15 ± 0.69

0.09 ± 0.62

0.04 ± 0.52

0.01 ± 0.56

0.10 (−0.05, 0.27)

0.10 (−0.03, 0.28)

0.10 (−0.03, 0.02)

0.05 (−0.03, 0.17)

0.16 ± 0.30

0.13 ± 0.33

0.10 ± 0.27

0.07 ± 0.18

Change in serum creatinine - mg/dL

0.30 (0.00, 0.70)

0.20 (−0.20, 0.60)

0.10 (−0.10, 0.40)

0.00 (−0.30, 0.30)

0.15 ± 0.30

0.12 ± 0.26

0.09 ± 0.20

0.06 ± 0.17

0.31 ± 0.54

0.22 ± 0.52

0.16 ± 0.46

−0.00 ± 0.47

−1.59 (−9.65, 3.71)

−3.70 (−12.06, 4.09)

−5.53 (−13.11, 0.79)

48 h

72 h

96 h

−1.95 (−8.46, 2.79)

24 h

−4.35 (−11.06, 1.74)

−3.71 (−10.67, 0.87)

−4.12 (−8.87, 1.89)

−2.58 (−7.83, 1.53)

−5.56 ± 13.85

−4.47 ± 13.37

−3.34 ± 12.52

−2.75 ± 9.43

Mean

High dose spironolactone

−4.13 ± 11.58

−4.53 ± 12.05

−3.33 ± 11.15

−2.54 ± 10.80

Change in estimated glomerular filtration rate - ml/min/1.73 m2

0.10 (−0.30, 0.40)

0.00 (−0.40, 0.30)

Usual care alone

Change in serum potassium – mEq/L

High dose spironolactone
Median

48 h

24 h

Usual care alone

0.56

0.82

0.95

0.87

0.77

0.85

0.67

0.76

0.08

0.08

0.02

0.50

P
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Changes in serum potassium concentration and renal function
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